Page last updated: 2024-08-23

daunorubicin and azd5438

daunorubicin has been researched along with azd5438 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ceckova, M; Hofman, J; Morell, A; Novotna, E; Sorf, A; Staud, F; Wsol, V	1

Other Studies

1 other study(ies) available for daunorubicin and azd5438

Article	Year
Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochemical pharmacology, 2019, Volume: 163 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cloning, Molecular; Daunorubicin; Dogs; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Heart Diseases; Humans; Imidazoles; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Protein Binding; Pyrimidines	2019

Article

Year

Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters.

Biochemical pharmacology, 2019, Volume: 163

Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cloning, Molecular; Daunorubicin; Dogs; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Heart Diseases; Humans; Imidazoles; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Protein Binding; Pyrimidines

2019